20.6 C
New York
Wednesday, June 10, 2026

Tag: exercise

Dancewear Market to Reach $2.2 billion, Globally, by 2035 at 4.8% CAGR: Allied Market Research

The dancewear market is witnessing steady adoption across dance academies, professional dance companies, fitness centers, educational institutions, performance arts organizations, and individual consumers due...

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering-related expenses, are expected to be approximately $600 million. All of the shares and pre-funded warrants in the Offering are to be sold by Tango. The Offering is expected to close on or about June 11, 2026, subject to customary closing conditions. In addition, Tango has granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount.

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Mingteng International Corporation Inc. Announces Pricing of $2.26 Million Registered Direct Offering

Jiangsu, China, June 09, 2026 (GLOBE NEWSWIRE) -- Mingteng International Corporation Inc. (Nasdaq: MTEN) (the “Company”) today announced that it has entered into a securities purchase agreement with certain institutional investors for the sale of up to 1,131,004 Class A ordinary shares, par value $0.00005 per share (“Class A Ordinary Shares”), at a purchase price of $2.00 per share, and pre-funded warrants to purchase Class A Ordinary Shares at an original exercise price of $2.00, with $1.99995 of the original exercise price pre-funded at the closing, and a remaining exercise price of $0.00005 per Class A Ordinary Share.

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common...

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq

ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule...

Mission Produce® Announces Fiscal 2026 Second Quarter Financial Results

Acquisition of Calavo Growers completed May 28, 2026

FutureCorp Space Acquisition 1 Completes $230,000,000 Initial Public Offering

New York, NY, June 08, 2026 (GLOBE NEWSWIRE) -- FutureCorp Space Acquisition 1 (the “Company”) announced today the closing of its initial public offering of 23,000,000 units, which includes 3,000,000 units issued pursuant to the exercise by the underwriters of their over-allotment option in full. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000. The Company’s units began trading on June 5, 2026 on The New York Stock Exchange (“NYSE”) under the ticker symbol “FTRAU.” Each unit consists of one Class A ordinary share of the Company and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share of the Company at an exercise price of $11.50 per share, subject to certain adjustment. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on NYSE under the symbols “FTRA” and “FTRAW,” respectively. Of the proceeds received from the consummation of the initial public offering (including the exercise of the over-allotment option) and a simultaneous private placement of warrants, $230,000,000 (or $10.00 per unit sold in the offering) was placed in trust.

Stark Power to Acquire Sagebrush Infrastructure Partners, Securing 5.6 GW U.S. Data Center Pipeline

Acquisition creates a premier "Time-to-Power" platform in the Central U.S., backed by an industry-leading development team.TEL AVIV, Israel, June 8, 2026 /PRNewswire/ -- Stark...

Helius Minerals Provides Status Update on Serra Pelada Project Acquisition Transaction

VANCOUVER, BC, June 8, 2026 /CNW/ - Helius Minerals Limited ("Helius" or the "Company") (TSXV: HHH) is pleased to provide an update on the status...

EXURA Launches Four-Product Equipment Line for Knees Over Toes (ATG) Training

Miami-based Amazon brand introduces a slant board, two tib bar models, and a forearm rotator for athletes following the methodology popularized by coach Ben Patrick
Miami-based Amazon brand introduces a slant board, two tib bar models, and a forearm rotator for athletes following the methodology popularized by coach Ben Patrick

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsExercise